Initiation of Insulin Aspart in Type 2 Diabetes

Novo Nordisk A/S6 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to investigate if using insulin aspart as start therapy will improve the efficacy on daytime blood glucose cycle profile in subjects with type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin aspartDRUG

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes for at least 3 years * HbA1c greater than 8.0% * Body Mass Index (BMI) below 40.0 kg/m2 * Inadequate treatment with diet and OADs * Never received treatment with insulin Exclusion Criteria: * Type 1 diabetes * Known or suspected allergy to investigational product

Locations (1)

Novo Nordisk Investigational Site

Montpellier, France

Outcomes

Primary Outcomes

Blood glucose value

Time frame: at 5 pm in a daytime blood glucose cycle profile

Secondary Outcomes

Evaluation of 24-hour blood glucose cycle

HbA1c

Hypoglycaemic episodes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.